Read More

Neoleukin Therapeutics Announced Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at ASH 2021

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Expos

NLTX